Tissue damage leads to rupture of vessels which triggers hemostatic mechanism. Hemostasis is a physiological mechanism of the body, wherein vessels contract, platelet plugs are formed, and coagulation starts, resulting in a stable fibrin network. Fibrinolysis is activated during this mechanism. Fibrinolysis is a physiological process in which blood clots are dissolved and tissue damage is remolded. Antifibrinolytic drugs are used to induce clot formation and to prevent blood loss in traumatic injuries. These drugs inhibit the activation of plasminogen to plasmin, thus preventing fibrinolysis and maintaining clot stability. Antifibrinolytic drugs are commonly known as fibrinolytic inhibitors. Reduction of fibrinolytic activity with antifibrinolytic drugs is important in trauma and surgery to control blood loss. People suffering from bleeding disorders such as hemophilia A and B, Von Willebrand disease, and platelet dysfunctions are often treated with fibrinolytic inhibitors or antifibrinolytic drugs. Currently, epsilon-aminocaproic acid (EACA) and tranexamic acid (TA or AMCA) are the synthetic antifibrinolytic drugs available in the market. EACA is a synthetic derivative of lysine and has a strong inhibiting effect on plasminogen. TA is found to be 10 times more effective than epsilon-aminocaproic acid.
The global antifibrinolytic drugs market is anticipated to expand during the forecast period due to rise in severe road accidents, complicated medical surgeries and procedures, prevalence of angioedema, and rise in the high-risk geriatric population globally. Trauma is the second largest cause of death in people aged between five and 45 years. Each year, about three million people die due to trauma. Injuries to the central nervous system and multi-organ failure cause severe bleeding problems. In such cases, antifibrinolytic drugs play a key role in preventing lysis of clot and loss of blood. Antifibrinolytic drugs are given to patients, undergoing cardiovascular surgeries, to prevent excessive bleeding. High prevalence of bleeding disorders and rise in major surgical procedures drive the global antifibrinolytic drugs market.
The global antifibrinolytic drugs market can be segmented based on drug type, application, end-user, and region. In terms of drug type, the global market can be divided into Trasylol, Aminocaproic acid, RiaSTAP, Aprotinin, Tranexamic acid injection, Tranexamic acid oral, Lysteda, and Fibrinogen, human.
Based on application, the global antifibrinolytic drugs market can be categorized into gynecology, gastrointestinal bleeding, hereditary angioedema, hemorrhage, bleeding in nose and mouth, fibrinolytic response testing, and surgeries. The gynecology segment can be further divided into medical conditions such as menorrhagia, pregnancy, parturition, and gynecological surgeries. The surgeries segment includes dental surgeries, cardiovascular surgeries, and neurosurgeries. In terms of end-user, the global antifibrinolytic drugs market can be segmented into hospitals, ambulatory surgical centers, clinics, and health care specialty processes.
In terms of region, the global antifibrinolytic drugs market can be segmented into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa. North America dominates the market in terms of revenue and is anticipated to continue its dominance during the forecast period from 2017 to 2025. Rise in awareness about antifibrinolytic drugs is likely to augment the market in North America. Growth of the market in North America can also be attributed to substantial investments in R&D and health care expenditure by the government and private players. Europe holds the second largest share of the global antifibrinolytic drugs market owing to mandatory medical insurance in countries such as Germany and France, high disposable income, and high research & development in the health care sector. The market in Asia Pacific and Middle East & Africa is attributed to expand at a significant pace during the forecast period.
Key players operating in the global antifibrinolytic drugs market are Acic Fine Chems, Xanodyne Pharmaceuticals, and Aurobindo Pharma Ltd.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.